Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31448683 | 0.89 | CYP2A13 (0.69) | ALDH1A1ATMCYP2A13SIGMAR1POLB | |
| Hydrochloric Acid SCHEMBL4221800 | 0.89 | ATM (0.55) | ALDH1A1ATMCYP2A13SIGMAR1POLB | |
| Trifluoroacetic Acid SCHEMBL1921312 | 0.87 | SIGMAR1 (0.56) | ALDH1A1ATMCYP2A13SIGMAR1POLB | |
| SCHEMBL6943859 | 0.87 | ATM (0.49) | ALDH1A1ATMCYP2A13SIGMAR1POLB | |
| SCHEMBL3589864 | 0.83 | MAOA (0.52) | ALDH1A1ATMSIGMAR1MAOAMAOB | |
| SCHEMBL29767452 | 0.83 | CXCR4 (0.69) | ALDH1A1ATMCYP2A13SIGMAR1POLB | |
| SCHEMBL16226380 | 0.83 | ALDH1A1 (0.81) | ALDH1A1ATMCYP2A13POLBKMT2A | |
| SCHEMBL8551446 | 0.83 | ALDH1A1 (0.64) | ALDH1A1ATMCYP2A13SIGMAR1POLB | |
| SCHEMBL12013928 | 0.83 | ACHE (0.68) | ALDH1A1ATMCYP2A13SIGMAR1POLB | |
| Methane SCHEMBL3600037 | 0.82 | MAOA (0.51) | ALDH1A1ATMSIGMAR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-04-17 | — | — | US | disclosed |
| US-11963954-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-23 | — | — | US | disclosed |
| CN-114685519-B | Pyranocarbazole alkaloid derivatives and application thereof in treating Alzheimer's disease | 中国医学科学院药物研究所 | 2023-09-26 | — | — | CN | disclosed |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| CN-114685519-A | Pyrano-carbazole alkaloid derivative and application thereof in treating Alzheimer's disease | 中国医学科学院药物研究所 | 2022-07-01 | — | — | CN | disclosed |
| EP-3349743-B1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | ST JUDE CHILDRENS RES HOSPITAL (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11236122-B2 | Triterpene amine derivatives | DFH THERAPEUTICS (US) | 2022-02-01 | — | — | US | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-08-19 | — | — | US | disclosed |
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| CN-1292789-A | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AWANDIS PHARMACEUTICAL CORP (US) | 2001-04-25 | — | — | CN | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253627-A1 | TRITERPENE AMINE DERIVATIVES | BET1, PGGT1B, NFATC1 | ALDH1A1 3332/4885ATM 3591/4885CYP2A13 188/4885 |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | ALDH1A1 2147/4885ATM 2098/4885CYP2A13 3915/4885 |
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | CUL3, CUL1, CUL5 | ALDH1A1 1133/4885ATM 3142/4885CYP2A13 1532/4885 |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | ALDH1A1 1996/4885ATM 3318/4885CYP2A13 1575/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | ALDH1A1 1996/4885ATM 3318/4885CYP2A13 1575/4885 |
| US-11963954-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | ALDH1A1 1996/4885ATM 3318/4885CYP2A13 1575/4885 |
| US-11236122-B2 | Triterpene amine derivatives | BET1, PGGT1B, NFATC1 | ALDH1A1 3332/4885ATM 3591/4885CYP2A13 188/4885 |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | ALDH1A1 1996/4885ATM 3318/4885CYP2A13 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.